Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment

NEURO-ONCOLOGY

OXFORD UNIV PRESS INC

1. NCI NIH HHS [R01 CA082500, U01 CA176110] Funding Source: Medline